Australia markets open in 17 minutes

Amplia Therapeutics Limited (ATX.XA)

Cboe AU - Cboe AU Real-time price. Currency in AUD
Add to watchlist
0.08600.0000 (0.00%)
At close: 03:54PM AEST
Full screen
Previous close0.0860
Open0.0870
Bid0.0720 x N/A
Ask0.0920 x N/A
Day's range0.0860 - 0.0870
52-week range0.0700 - 0.1150
Volume20,000
Avg. volume19,203
Market capN/A
Beta (5Y monthly)0.52
PE ratio (TTM)N/A
EPS (TTM)-0.0250
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US

    Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), is pleased to announce that the US FDA have cleared Amplia's IND application for a trial of Amplia's best-in-class focal adhesion kinase (FAK) inhibitor narmafotinib in pancreatic cancer. The proposed trial will explore the safety, tolerability and efficacy of a combination of narmafotinib with the chemotherapy regime FOLFIRINOX.

  • PR Newswire

    AACR OVARIAN CANCER CONFERENCE PRESENTATION

    Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company") is pleased to announce that a poster, detailing a series of preclinical studies in ovarian cancer models, was presented at the American Association for Cancer Research (AACR) Special Conference In Cancer Research: Ovarian Cancer meeting, held in Boston, USA over the weekend. The poster describes research with narmafotinib (AMP945) conducted by the company's collaborators at the University of California, San Diego (UCSD), and was

  • PR Newswire

    AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer

    Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") is pleased to announce new data showing the efficacy of its investigational FAK inhibitor, AMP945, in a preclinical model of pancreatic cancer, when used in combination with FOLFIRINOX treatment. FOLFIRINOX, a combination of four chemotherapies used in the treatment of pancreatic cancer patients, is currently a widely-used treatment in many major markets around the world including the US.